Inactive

The Centers for Disease Control and Prevention intends to award a SOLE SOURCES JUSTIFICATION for firm fixed price purchase order to Agilent Technologies, Inc.. We propose to contract for Agilent xCELL... The Centers for Disease Control and Prevention intends to award a SOLE SOURCES JUSTIFICATION for firm fixed price purchase order to Agilent Technologies, Inc.. We propose to contract for Agilent xCELLigence Real-Time Cell Analysis (RTCA) MP instrument uses label-free cellular impedance to continuously monitor cell health, behavior, and function with high accuracy, sensitivity, and reproducibility. The MP model can host up to six 96-well electronic microplates (E-Plate 96), which can be run in parallel or independently of one another. This multiple plate format is ideal for cell health characterization, immune cellmediated killing, viral cytopathic effects, cytotoxicity, cell adhesion, cell barrier function (TEER), cell signaling (e.g., GPCR) and other related applications. The instrument operates in a standard CO2 cell culture incubator and the control unit is housed outside the incubator. Online data acquisition and offline data analysis are easy to perform using RTCA Software Pro, which also supports FDA 21 CFR Part 11. This contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under the authority of 6.302-1 and 10 USC 3406. Interested persons may identify their interest and capability to respond to the requirement or submit proposals. This notice of intent is not a request for competitive quotations; however, all quotations/responses received within fifteen (15) days of the issuance of this notice will be considered by the government. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be emailed to contract specialist at vwa8@cdc.gov by COB 27, August 2024.